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SIRT2 deacetylates specific acetyllysine residues in
diverse proteins and is implicated in a variety of
cellular processes. SIRT2 inhibition thus has poten-
tials to treat human diseases such as cancers and
neurodegenerative disorders. We have recently
developed a series of ε-trifluoroacetyllysine-contain-
ing macrocyclic peptides, which inhibit the SIRT2
activity more potently than most other known inhibi-
tors. Here, we report the crystal structure of human
SIRT2 in complex with a macrocyclic peptide inhibi-
tor, S2iL5, at 2.5 A˚ resolution. The structure revealed
that S2iL5 binds to the active site of SIRT2 through
extensive interactions. A structural comparison of
the SIRT2-S2iL5 complex with SIRT2 in the free
form, and in complex with ADP-ribose, revealed
that S2iL5 induces an open-to-closed domain move-
ment and an unexpected helix-to-coil transition in a
SIRT2-specific region. Our findings unveil the poten-
tial ofmacrocyclic peptides to bind target proteins by
inducing dynamic structural changes.
INTRODUCTION
Sirtuins are a family of evolutionarily conserved, nicotinamide
adenine dinucleotide (NAD+)-dependent deacetylases (Sauve
et al., 2006). The seven mammalian sirtuins, SIRT1–SIRT7,
have distinct substrate specificities and subcellular localizations
and are implicated in a variety of biological processes, such as
gene silencing, cell-cycle regulation, metabolism, apoptosis,
longevity, and cancer (Baur et al., 2012). SIRT2 is primarily local-
ized in the cytoplasm and nucleus, and it deacetylates specific
acetyllysine residues in diverse proteins. For instance, the
SIRT2-catalyzed deacetylation of a-tubulin (Inoue et al., 2007;
North et al., 2003) and histone H4 (North et al., 2003; Vaquero
et al., 2006) functions in the regulation of cell-cycle progression,Structure 22, 34and its deacetylation of receptor-interacting protein 1 (RIP1) is
responsible for the modulation of RIP1–RIP3 complex formation
and thus regulates programmed necrosis (Narayan et al., 2012).
In addition, the siRNA-mediated downregulation of SIRT2
induces apoptosis in HeLa cells, caused by p53 accumulation
(Li et al., 2011). Moreover, SIRT2 is associated with the aggrega-
tion of neural proteins such as a-synuclein (Outeiro et al., 2007)
and huntingtin (Chopra et al., 2012), and thus SIRT2 inhibition
prevents neurodegeneration in Parkinson’s disease (Outeiro
et al., 2007) and Huntington’s disease (Chopra et al., 2012)
models. Collectively, the specific inhibition of SIRT2 has tremen-
dous potentials to treat various human diseases.
High-throughput and in silico screening campaigns have
identified more than a dozen distinct inhibitors against a family
of sirtuins (Chen, 2011), including SRT1720 (Nguyen et al.,
2013), Ex-527 (Gertz et al., 2013), Suramin (Schuetz et al.,
2007), thieno[3,2-d]pyrimidine-6-carboxamide-based inhibitors
(Disch et al., 2013), and indole-based inhibitors (Napper et al.,
2005). Crystallographic studies revealed that SRT1720 (Nguyen
et al., 2013) and Ex-527 (Gertz et al., 2013) occupy the peptide
substrate- and NAD+-binding sites of sirtuins, respectively and
that Suramin (Schuetz et al., 2007) and the thieno[3,2-d]pyrimi-
dine-6-carboxamides (Disch et al., 2013) occupy both the
peptide substrate- and NAD+-binding sites. In addition, several
mechanism-based peptidic inhibitors have also been developed
(Zheng, 2013). These inhibitors have an inert or poorly reactive
moiety, such as ε-trifluoroacetylamide on lysine (KTfa) (Smith
and Denu, 2007), which probably occupies the ε-acetylamide
binding site of sirtuins. However, most of these inhibitors exhibit
modest potency and isoform-selectivity. Recently, we con-
structed a library of KTfa-containing macrocyclic peptides and
screened for active species that strongly bind SIRT2 (Morimoto
et al., 2012) by means of the random nonstandard peptide inte-
grated discovery (RaPID) system (Hipolito and Suga, 2012;
Yamagishi et al., 2011). The discovered macrocyclic peptides
are able to bind SIRT2 with dissociation constants (KDs) in the
low nanomolar range, and they inhibit the deacetylase activity
with a similar range of IC50 values. Macrocyclic peptides usually
show increased protease-resistance and potentially better cell
permeability than linear peptides and thus can serve as a5–352, February 4, 2014 ª2014 Elsevier Ltd All rights reserved 345
Table 1. Data Collection and Refinement Statistics
SIRT2-S2iL5
Data Collection
Space group P212121
Cell dimensions
a, b, c (A˚) 91.18, 135.61, 148.83
a, b, g () 90, 90, 90
Resolution (A˚) 50.0–2.52 (2.56–2.52)a
Rsym 0.148 (0.410)
I/sI 14.8 (3.4)
Completeness (%) 98.6 (96.6)
Redundancy 5.2 (3.9)
Refinement
Resolution (A˚) 46.6–2.52 (2.56–2.52)
No. reflections 61,346
Rwork/Rfree 0.216/0.263
No. atoms
Protein 9,323
Ligand/ion 644
Water 507
B-factors
Protein 36.1
Ligand/ion 24.5
Water 27.6
Rmsd
Bond lengths (A˚) 0.003
Bond angles () 0.605
aValues in parentheses are for highest-resolution shell.
Structure
Structure of a SIRT2-Macrocyclic Peptide Complexpreferred scaffold for drug development, as exemplified by
the immunosuppressive cyclic peptide cyclosporin A (Huai
et al., 2002). Although the RaPID system is a suitable technology
to discover such potent macrocyclic peptides, including the
aforementioned anti-SIRT2 inhibitors, it remains unclear how
these macrocyclic peptides strongly bind SIRT2 and exhibit their
inhibitory activities.
RESULTS AND DISCUSSION
Crystal Structure of HumanSIRT2 inComplexwith S2iL5
To gain structural insights into their inhibitory mechanisms, we
performed crystallization screening of human SIRT2 in the pres-
ence of several macrocyclic peptides and successfully deter-
mined the crystal structure of SIRT2 in complex with one of the
inhibitor peptides, S2iL5, at 2.5 A˚ resolution (Table 1 and Fig-
ure 1). The structure revealed that SIRT2 consists of a large
Rossmann-fold domain (residues 55–91, 146–186, and 241–
356) and a small zinc-binding domain (residues 92–145 and
187–240) (Figure 1A and Figure S1A available online), as in the
structure of SIRT2 in the free form (Finnin et al., 2001) (Figures
1B and S1B). The asymmetric unit contains four SIRT2–S2iL5
complexes (Mol A–Mol D), which are essentially identical (root-
mean-square deviation [rmsd] values for Ca atoms are <0.70 A˚)
(Figures S1C and S1D). Thus, we will hereafter describe Mol A.346 Structure 22, 345–352, February 4, 2014 ª2014 Elsevier Ltd All rS2iL5 consists of 14 amino acid (aa) residues cyclized via a
thioether bond (Figure 2A) and exhibits remarkably high affinity
and inhibitory activity against SIRT2 (KD = 1.0 nM at 10
C and
IC50 = 13 nM at 37
C) (Figures 2B, 2C and S2A). The bound
S2iL5 is clearly defined in the FO – FC omit electron density
map (Figure 1C; the SIRT2 and S2iL5 residues are denoted by
the three-letter and one-letter codes, respectively). S2iL5 adopts
a cyclic structure, which is stabilized by multiple intramolecular
hydrogen bonds. The side chain of R8 is flipped inside the cyclic
scaffold, and its guanidine head is nearly in the center. This posi-
tioning of the guanidine head is supported by direct hydrogen
bonds with the carbonyl groups of Y4 and V6 and water-medi-
ated hydrogen bonds with the carbonyl groups of R9 and N11.
This R8 residue adjacent to the KTfa is highly conserved among
the selected macrocyclic peptide inhibitors (Morimoto et al.,
2012), suggesting that it plays a crucial role in maintaining their
tertiary structural integrity. Moreover, hydrogen-bonding inter-
actions are formed between T3 and V6 and between H2 and
the carbonyl group around the thioether linkage. This structure
allows the presentation of the KTfa7 side chain outside the cyclic
scaffold, for binding to SIRT2. We refer to this peptide structure
as a ‘‘power button icon’’-like (PBI-like) macrocycle, due to the
shape similarity (Figure 2A).
S2iL5 Recognition by SIRT2
S2iL5 binds to the active-site groove between the small and
large domains of SIRT2, with the KTfa7 side chain inserted into
the catalytic tunnel formed by His187, Val233, and Phe235
(Figures 1D and 3A). The present structure confirmed that the
KTfa residue occupies the acetyllysine-binding site of sirtuin.
The hydrocarbon chain of KTfa7 is sandwiched by the side chains
of His187 and Phe235, with its Nε atom hydrogen bonded to
the carbonyl group of Val233 (Figures 1D and 3A). The amide
and carbonyl groups of KTfa7 hydrogen bond with the carbonyl
group of Glu237 and the amide group of Gly236 in the small
domain, respectively. In addition, the amide and carbonyl groups
of R8 hydrogen bond with the carbonyl and amide groups of
Gln267 in the large domain, respectively. Consequently, SIRT2
and S2iL5 (KTfa7 and R8) form an intermolecular b sheet-like
interaction (Figures 1D and 3A). His187, Val233, and Phe235
are highly conserved among the sirtuin family members
(Figure S3), and the acetyllysine residues of the substrate
peptides are recognized in a similar manner in other sirtuin-
substrate peptide complex structures (Avalos et al., 2002;
Cosgrove et al., 2006; Du et al., 2011; Jin et al., 2009; Zhou
et al., 2012). For instance, in the SIRT3-AceCS-KAc complex
structure, the side chain of KAc642 is sandwiched by the side
chains of His248 and Phe294, with its Nε atom hydrogen bonded
to the carbonyl group of Val292 (Jin et al., 2009) (Figure 3B). The
amide and carbonyl groups of KAc642 hydrogen bond with the
carbonyl group of Glu296 and the amide group of Gly295,
respectively, and the amide and carbonyl groups of V643
hydrogen bond with the carbonyl and amide groups of Glu325,
respectively.
In addition to these interactions commonly observed in sir-
tuins, S2iL5 forms a number of hydrophilic and hydrophobic in-
teractions with SIRT2, with a buried surface area of 845 A˚2
(42% of the total surface area of S2iL5), which is larger than
that for the SIRT3-AceCS-KAc complex (582 A˚2) (Figures 1Dights reserved
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Figure 1. Crystal Structure of SIRT2
(A and B) Overall structures of SIRT2 in complex with S2iL5 (A) and in the free form (PDB ID 1J8F) (B). The small and large domains are colored yellow-green and
cyan, respectively. S2iL5 is shown as a stickmodel, in which the carbon atoms are yellow, oxygen atoms are red, nitrogen atoms are blue, and the fluorine atom is
gray. The bound zinc ion is shown as a gray sphere. The cofactor-binding loop (residues 92–104) and the SIRT2-specific insertion (residues 289–304) are colored
green and magenta, respectively. The disordered region (residues 99–103) in the S2iL5 complex is indicated by green dots in (A). In (B), the N-terminal a0 helix
(residues 34–45) is omitted for clarity.
(C) Structure of S2iL5 (stereo view). ThemFO –DFC omit electron densitymap for S2iL5 is shown as a graymesh (contoured at 4s). A water molecule is shown as a
red sphere.
(D) S2iL5 recognition by SIRT2 (stereo view). Hydrogen bonds are shown as green dashed lines in (C) and (D).
See also Figure S1.
Structure
Structure of a SIRT2-Macrocyclic Peptide Complexand 3A). The R9 side chain of S2iL5 forms salt bridges
with Glu116 and Glu120, and a cation-p interaction with
Phe235. Y4, H5, and T10 of S2iL5 hydrogen bond with Ser271,
Leu239, and Gln265, respectively. The side chains of Y4 and
H5 in S2iL5 form van der Waals interactions with the side
chain of Phe244, which in turn forms an edge-to-face interaction
with Phe243. In addition, S2iL5 interacts with a SIRT2-specific
insertion loop (residues 289–304) in the large domain (Figures
1D and 3A). Y12 of S2iL5 hydrogen bonds with Asp294, and
Y1 and Y12 form van der Waals interactions with the side chain
Met299 and Phe296 and Met301, respectively. The insertion
loop is specific to SIRT2 (Figure S3), thus partly explaining why
S2iL5 binds SIRT2 (KD = 1.0 nM) more potently than SIRT3
(KD = 1.8 nM) (Figure 2B). Altogether, the present structure re-
vealed that S2iL5 adopts a PBI-like structure to achieve exten-
sive interactions with SIRT2.Structure 22, 34Structural Change upon S2iL5 Binding
A comparison between the SIRT2 structures in complex with
S2iL5 and in the free form (Finnin et al., 2001) revealed the
conformational changes that occur in SIRT2 upon S2iL5 binding
(Figure 4A). First, the small domain moves toward the large
domain upon S2iL5 binding, as observed in other sirtuins (Avalos
et al., 2002; Cosgrove et al., 2006; Du et al., 2011; Jin et al., 2009;
Moniot et al., 2013; Zhou et al., 2012) (Figure 4A). This open-to-
closed domain movement allows Phe235 to form the catalytic
tunnel and enables Gly236, Glu237, and Gln267 to form the b
sheet-like interactions with S2iL5 (Figure 4B). Second, the
SIRT2-specific insertion (residues 289–304) adopts a loop
conformation to interact with S2iL5 in the S2iL5 complex,
whereas it forms an a helix in the free form (Finnin et al., 2001)
(Figure 4B). The side chain of Asp294 hydrogen bonds with the
amide groups of Phe296 and Gly302, to stabilize the loop5–352, February 4, 2014 ª2014 Elsevier Ltd All rights reserved 347
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Figure 2. S2iL5 Binding to SIRT2
(A) Chemical structure of S2iL5. The peptide is cyclized via a thioether bond between Y1 and C14.
(B) Binding of S2iL5 to the alanine mutants of SIRT2.
(C) Binding of the S2iL5 mutants to SIRT2. In (B) and (C), the KD values were determined by SPR experiments and are shown as means ± SD (n = 3).
See also Figure S2.
Structure
Structure of a SIRT2-Macrocyclic Peptide Complexconformation. Third, S2iL5 binding induces a local conforma-
tional change, including the rotation of the side chains of
Phe243 and Phe244, which are involved in the interactions
with S2iL5 (Figure 4B).
The crystal structure of SIRT2 in complex with ADP-ribose
(ADPr), a product analog, was reported recently (Moniot et al.,
2013). A comparison between the SIRT2 structures in complex
with S2iL5 and ADPr revealed that ADPr binding induces a
local structural change in a so-called cofactor-binding loop
(residues 92–104) (Figures 4C and S4A). Residues 99–103 in
the cofactor-binding loop are disordered in the S2iL5 complex,
whereas they are ordered and involved in the recognition of
ADPr in the ADPr complex. Phe96, Arg97, and Tyr104 interact
with the nicotinamidic-ribose of ADPr, and Arg97 interacts with
the phosphate group of ADPr. In addition, Lys287 in the large
domain interacts with the adenine ring of ADPr. In SIRT3, the
cofactor-binding loop adopts a closed conformation and
Arg158 interacts with ADPr in the ADPr complex, whereas it
adopts an open conformation in the free form and the AceCS-
KAc complex (Jin et al., 2009) (Figure S4B). In contrast, in the
SIRT2-S2iL5 complex, the cofactor-binding loop adopts a
partially closed conformation without cofactor binding, because
Arg97 forms a salt bridge network with Glu116 in the small
domain and R9 of S2iL5 (Figures 4C and S4A). Unlike the
SIRT2-S2iL5 complex, Arg158 cannot form a salt bridge network
with Glu177 and AceCS-KAc in the SIRT3-AceCS-KAc complex,
because R9 of S2iL5 corresponds to M644 of AceCS-KAc.
The two domains in the ADPr complex adopt a closed con-
formation, as observed in the S2iL5 complex (Moniot et al.,
2013) (Figure 4A). However, in the ADPr complex, the SIRT2-
specific insertion mimics a substrate peptide and interacts with
the active-site groove of a neighboring SIRT2 molecule in the
crystallographic asymmetric unit. This observation suggested348 Structure 22, 345–352, February 4, 2014 ª2014 Elsevier Ltd All rthat the closed conformation observed in the ADPr complex is
not due to ADPr binding, but rather to crystal packing inter-
actions. This is consistent with the notion that the peptide
substrate, but not the cofactor NAD+, induces an open-to-closed
domain movement (Cosgrove et al., 2006). This mechanism was
also reported for other sirtuins. The crystal structure of SIRT3,
along with isothermal titration calorimetry experiments, indi-
cated that the binding of the peptide substrate to SIRT3 supports
the binding of NAD+ (Jin et al., 2009). In addition, the crystal
structures of a bacterial sirtuin revealed that the binding of the
peptide substrate induces an open-to-closed domainmovement
(Hoff et al., 2006).
A comparison between the SIRT2 structures in the free
form (Finnin et al., 2001) and in the complex with S2iL5 and
ADPr (Moniot et al., 2013) revealed that the SIRT2-specific
insertion can adopt different conformations (Figure 4A). A com-
parison between the S2iL5 and ADPr complexes indicated that
the insertion loop in the ADPr complex interferes with the b
sheet-like interaction between S2iL5 and SIRT2 in the S2iL5
complex (Figure 4C), suggesting that the insertion loop in the
ADPr complex is displaced for the substrate peptide binding.
Given that this flexible SIRT2-specific insertion is involved in
the interaction with S2iL5 (in the S2iL5 complex) and a neigh-
boring SIRT2 molecule (in the free form and ADPr complex), it
may play a role in the recognition of the substrate peptides,
although further studies will be required to elucidate its physio-
logical function.
Mutational Analysis
To confirm the functional significance of the observed inter-
actions between SIRT2 and S2iL5, we determined the KD values
between S2iL5 and alanine mutants of SIRT2, by surface plas-
mon resonance (SPR) (Figures 2B and S2A). The F244A mutantights reserved
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Figure 3. Structural Comparison of the
SIRT2-S2iL5 and SIRT3-AceCS-KAc Com-
plexes
(A) Structure of SIRT2 in complex with S2iL5. The
SIRT2-specific insertion (residues 289–304) is
colored magenta.
(B) Structure of SIRT3 in complex with AceCS-KAc
(PDB ID 3GLR) (Jin et al., 2009). The bound pep-
tides are colored yellow, and the hydrogen bonds
are shown as dashed green lines in (A) and (B).
See also Figure S3.
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Structure of a SIRT2-Macrocyclic Peptide Complexshowed the most pronounced reduction in the affinity for
S2iL5 (KD = 4.0 nM), confirming the importance of the inter-
actions between Phe244 and S2iL5. The E116A and E120A
mutants showed reduced affinity for S2iL5 (KD = 1.7 and
2.2 nM, respectively), establishing the importance of the salt
bridges between R9 of S2iL5 and Glu116 and Glu120 of
SIRT2. The Q265A and S271A mutants showed reduced affinity
for S2iL5 (KD = 1.8 and 1.8 nM, respectively), confirming the
importance of the hydrogen-bonding interactions between T10
and Gln265 and between Y4 and Ser271. The D294A mutant
showed reduced affinity (KD = 1.4 nM), suggesting the functional
significance of the helix-to-coil transition in the SIRT2-specific
insertion for S2iL5 binding. In contrast, the F296A, M299A, and
M301A mutants showed almost no reduction in their affinities
for S2iL5, possibly because S2iL5 binds to SIRT2 through multi-
ple interactions. We also determined the KD values between
SIRT2 and alanine mutants of S2iL5 (Figures 2C and S2B).
Among the S2iL5 mutants tested, the R9A mutant showed the
most pronounced reduction in the affinity for SIRT2 (KD =
7.9 nM), confirming the importance of the salt bridges between
R9 of S2iL5 and Glu116 and Glu120 of SIRT2. This result is
consistent with the increased KD for the E116A and E120A
mutants of SIRT2. The R8A mutant exhibited reduced affinity
(KD = 3.8 nM), verifying the functional significance of the PBI-
like conformation of S2iL5, which is maintained by the R8-medi-
ated intramolecular hydrogen-bonding network. The Y4A and
H5A mutants showed reduced affinities (KD = 1.9 and 2.4 nM,
respectively). The Y4A/R9A/Y12A triple mutant showed an
additive decrease in the affinity (KD = 29 nM), as compared
with the single mutants (Y4A, R9A, and Y12A) and the double
mutants (Y4A/R9A, R9A/Y12A, and Y4A/Y12A). Notably, the
Y4A/R9A/Y12A mutant showed markedly reduced affinity (KD =
29 nM), as compared with the Y4A/R9A mutant (KD = 5.8 nM),
although the Y12A mutant showed no reduction in the affinity
(KD = 0.42 nM). These results indicated that the multiple inter-
actions synergistically contribute to the binding of S2iL5
to SIRT2. We further determined the KD values between
SIRT2 and a 14 aa linear peptide, in which the amino group of
Y1 in S2iL5 is acetylated, and a 5 aa short linear peptide corre-
sponding to H5-R9 of S2iL5. The 14 aa linear peptide showed
a marked decrease in the affinity (KD = 6.8 nM), whereas theStructure 22, 345–352, February 4, 20145 aa linear peptide showed a drastic
reduction in the affinity (KD = 145 nM).
Altogether, our mutational analyses
confirmed the functional significance of
the observed binding mode betweenSIRT2 and S2iL5 and indicated the synergistic contributions
of the multiple interactions.
Structural Plasticity of Macrocyclic Peptide Inhibitors
Using the RaPID system (Hipolito and Suga, 2012; Yamagishi
et al., 2011), we previously developed macrocyclic peptide in-
hibitors against a variety of enzymes, such as SIRT2 deacetylase
(Morimoto et al., 2012), E6AP ubiquitin ligase (Yamagishi et al.,
2011), and Akt2 kinase (Hayashi et al., 2012). These studies
demonstrated the potential of the RaPID system for the dis-
covery of macrocyclic peptide inhibitors with high selectivity
and potency. However, their inhibitory mechanisms have
remained unclear, because no crystal structure of an enzyme-
macrocyclic peptide complex has been solved. Recently, we
reported the crystal structures of a MATE multidrug transporter
in complex with in vitro selected macrocyclic peptides, MaD5
and MaL6, which selectively inhibit the drug extrusion activity
of the MATE transporter (Tanaka et al., 2013). The structures
revealed that MaD5 and MaL6 adopt lariat- and b-hairpin-like
structures, respectively, to bind the central cleft of the trans-
porter. Thus, the crystal structures of SIRT2 and MATE in com-
plex with the macrocyclic peptides highlighted the structural
plasticity of the macrocyclic peptides, which confers extremely
high affinities to various target proteins.
Notably, the present structure of SIRT2 in complex with S2iL5
further revealed that S2iL5 binding induces an unanticipated
conformational change in the flexible SIRT2-specific region.
Our functional data demonstrated the potential role of this
dynamic structural change for S2iL5 binding. It seems unlikely
that small molecule inhibitors could induce such large structural
changes in their target proteins, due to the limited number of
inhibitor-protein interactions. Thus, the ability to bind to a target
protein, by inducing a structural change within the target, is likely
to be a unique advantage for macrocyclic peptide inhibitors.
EXPERIMENTAL PROCEDURES
Chemical Synthesis of Macrocyclic Peptides
The S2iL5 peptide and its mutants were synthesized with amidated C termini
by standard 9-fluorenylmethyloxycarbonyl (Fmoc)-based solid phase peptide
synthesis. NovaPEG Rink Amide resin (Novabiochem) was used as the solid
support. For the cyclized peptides, after elongation of the peptide chain, theª2014 Elsevier Ltd All rights reserved 349
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Figure 4. Structural Change in SIRT2
(A) Comparison between the SIRT2 structures in
the free form (PDB ID: 1J8F; gray) and in the
complex with S2iL5 and ADPr (PDB ID: 3ZGV;
beige) (stereo view). The structures are super-
imposed based on their large domains. S2iL5 and
ADPr are shown as stick models. The bound zinc
ions are shown as spheres.
(B) Structural comparison of the S2iL5 complex
with the free form (PDB ID: 1J8F; gray) (stereo
view).
(C) Structural comparison of the S2iL5 complex
with the ADPr complex (PDB ID: 3ZGV; beige)
(stereo view). The disordered region (residues 99–
103) in the S2iL5 complex is indicated by green
dots. In (A)–(C), the S2iL5 complex is colored as in
Figure 1A.
See also Figure S4.
Structure
Structure of a SIRT2-Macrocyclic Peptide Complexresulting N-terminal a-amino group was chloroacetylated by an incubation
with a solution of 0.2 M chloroacetylN-hydroxysuccinimide ester inN,N-dime-
thylformamide (DMF), with rotation for 40 min at room temperature. For the
linear peptides, the N-terminal amino group was acetylated by an incubation
with a solution of 0.5 M acetic anhydride and 0.25 M N,N-diisopropylethyl-
amine in DMF for 40 min at room temperature. After washing the resin with
DMF (2 ml, three times) and DCM (2 ml, six times), the peptides were cleaved
from the resin and deprotected by an incubation with a solution of trifluoroace-
tic acid (TFA)/1,2-ethanedithiol/triisopropyl silane/water (92.5:2.5:2.5:2.5),
with rotation at room temperature for 3 hr. The solutions were concentrated350 Structure 22, 345–352, February 4, 2014 ª2014 Elsevier Ltd All rights reservedin vacuo, and the cleaved peptides were then
precipitated with diethyl ether. For cyclization,
the resulting peptide pellets were dissolved in
20 ml of water/DMSO (1:1), and triethylamine
was added to the solution to bring its pH to
approximately ten. After an incubation at room
temperature for 30 min to promote the cyclization,
the peptide solution was acidified by TFA and pu-
rified by reverse-phase high-performance liquid
chromatography (HPLC), using a gradient of eluent
B (0.1% TFA in acetonitrile) in eluent A (0.1% TFA
in water). The purified peptides were lyophilized
and dissolved in DMSO.
Protein Preparation
The gene encoding human SIRT2 (residues 1–370)
was amplified by PCR and cloned between the
NdeI and XhoI sites of the modified pET28a vector
(Novagen). The protein was expressed at 20C
in Escherichia coli Rosetta 2 (DE3) (Novagen) and
purified by Ni-NTA Superflow resin (QIAGEN).
The eluted protein was incubated with trypsin
(1:100, w/w) for 2.5 hr at 4C, because limited
trypsin proteolysis of SIRT2 was found to produce
a stable 36 kDa fragment, which was determined
to be SIRT2 (residues 43–370) using MALDI-TOF
mass spectrometry (MS). The protein was further
purified by chromatography on Resource Q (GE
Healthcare) and HiLoad Superdex 200 16/60
(GE Healthcare) columns. The purified protein
was concentrated using an Amicon Ultra 30K filter
(GE Healthcare). The expression vectors for the
SIRT2 mutants were generated by a PCR-based
method, using the expression vector for full-length
SIRT2 as a template, and the sequences were
verified by DNA sequencing. The mutant proteinswere expressed at 20C in E. coli Rosetta 2 (DE3) and purified with Ni-NTA
Superflow resin.
Crystallography
Purified SIRT2 (residues 43–370) was crystallized at 4C by the sitting-drop
vapor diffusion method. SIRT2 (10 mg ml–1) was mixed with S2iL5 at a 1:2
(SIRT2:S2iL5) molar ratio in 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, and
1 mM DTT. Crystals were obtained by mixing 0.5 ml of protein solution and
0.5 ml of reservoir solution (100 mM MES-NaOH, pH 7.0, 100 mM Li2SO4,
100 mM NaCl, and 8.5% PEG 4,000). X-ray diffraction data were collected
Structure
Structure of a SIRT2-Macrocyclic Peptide Complexat 100 K on the beamline BL32XU at SPring-8 (Hyogo, Japan). The crystals
were cryoprotected in reservoir solution supplemented with 30% ethylene
glycol. X-ray diffraction data were processed using HKL2000 (HKL Research).
The structure was determined by molecular replacement with MOLREP (Vagin
and Teplyakov, 2010), using the SIRT2 structure in the free form (Protein Data
Bank [PDB] ID: 1J8F) as a search model. The model was built manually using
COOT (Emsley and Cowtan, 2004) and refined using PHENIX (Adams et al.,
2002). The final model contains four SIRT2–S2iL5 complexes (residues
55–98 and 104–356 for Mol A, residues 56–100 and 107–356 for Mol B, resi-
dues 57–99 and 106–356 for Mol C, and residues 57–98 and 106–356
for Mol D), four zinc ions, four MES, four ethylene glycol, and 507 water mole-
cules. Molecular graphic images were prepared using CueMol (http://www.
cuemol.org).
Surface Plasmon Resonance Analysis
SPR measurements were performed at 10C on a Biacore T200 instrument
(GE Healthcare) equipped with a Ni-NTA sensor chip. Modified HBS-EP+
(10 mM HEPES-KOH, pH 7.4, 150 mM NaCl, 50 mM EDTA, 0.05% Tween
20, 0.1%DMSO) was used as the running buffer for all experiments. To collect
kinetics data, a series of five different concentrations of each peptide was
injected for 1 min at a flow rate of 30 ml min–1. Dissociation of the peptide
was allowed to continue for 1 min between injections and 5 min after the final
injection. Buffer blank injections were performed before and after the sample
injection for double referencing with a negative control surface without protein
immobilization, tomonitor the background binding. Binding sensorgramswere
fitted with the Biacore evaluation software.ACCESSION NUMBERS
The atomic coordinate and structure factor for the SIRT2-S2iL5 complex has
been deposited in the Protein Data Bank (PDB) under the accession code
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